Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Sell
41
GH Quote, Financials, Valuation and Earnings
Last price:
$30.43
Seasonality move
:
4.48%
Day range:
$30.14 - $31.38
52-week range:
$15.81 - $38.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.34x
P/B ratio:
28.68x
Volume:
1.2M
Avg. volume:
1.7M
1-year change:
8.64%
Market cap:
$3.8B
Revenue:
$563.9M
EPS (TTM):
-$4.24
Analysts' Opinion
-
Consensus RatingGuardant Health has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $42.30, Guardant Health has an estimated upside of 41.92% from its current price of $30.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $32.00 representing 100% downside risk from its current price of $30.44.
Fair Value
-
According to the consensus of 15 analysts, Guardant Health has 41.92% upside to fair value with a price target of $42.30 per share.
GH vs. S&P 500
-
Over the past 5 trading days, Guardant Health has underperformed the S&P 500 by -2.87% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Guardant Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Guardant Health has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Guardant Health reported revenues of $191.5M.
Earnings Growth
-
Guardant Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Guardant Health reported earnings per share of -$0.88.
Enterprise value:
3.9B
EV / Invested capital:
3.61x
Price / LTM sales:
5.34x
EV / EBIT:
--
EV / Revenue:
5.64x
PEG ratio (5yr expected):
-1.62x
EV / Free cash flow:
-14.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$417.5M
Return On Assets:
-30.37%
Net Income Margin (TTM):
-74.02%
Return On Equity:
-651%
Return On Invested Capital:
-42.02%
Operating Margin:
-61.28%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $430.8M | $535.8M | $692.3M | $143M | $191.5M | |
| Gross Profit | $288.1M | $324.1M | $417.5M | $85.4M | $117M | |
| Operating Income | -$496.5M | -$513.3M | -$515.1M | -$113.5M | -$117.3M | |
| EBITDA | -$552M | -$385.8M | -$467M | -$73.9M | -$96.5M | |
| Diluted EPS | -$5.93 | -$4.06 | -$4.24 | -$0.73 | -$0.88 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.6B | $1.1B | $1.3B | $1.2B | |
| Total Assets | $1.3B | $2.2B | $1.7B | $1.8B | $1.5B | |
| Current Liabilities | $72M | $102.3M | $175.1M | $226.8M | $197.3M | |
| Total Liabilities | $113.5M | $1.5B | $1.5B | $1.6B | $1.6B | |
| Total Equity | $1.1B | $768.8M | $166.7M | $228.3M | -$60.1M | |
| Total Debt | -- | $1.1B | $1.1B | $1.1B | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$295.7M | -$337M | -$254.1M | -$77.8M | -$51.1M | |
| Cash From Investing | -$187.5M | $247.4M | $391.6M | $260.7M | -$294.8M | |
| Cash From Financing | -$187.6M | $389.1M | $92.5M | $3.8M | -$2.9M | |
| Free Cash Flow | -$387.8M | -$363.4M | -$274.4M | -$80.2M | -$55.3M | |
GH
Sector
Market Cap
$3.8B
$45.9M
Price % of 52-Week High
79%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
8.64%
-32.15%
Beta (5-Year)
1.255
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$31.80
200-day SMA
Buy
Level
$26.07
Bollinger Bands (100)
Buy
Level
22.46 - 32.5
Chaikin Money Flow
Sell
Level
-13.6M
20-day SMA
Sell
Level
$34.31
Relative Strength Index (RSI14)
Sell
Level
40.96
ADX Line
Sell
Level
31.74
Williams %R
Buy
Level
-96.0448
50-day SMA
Buy
Level
$29.64
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-77.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.2632)
Sell
CA Score
(Annual)
Level (-3.5991)
Buy
Beneish M-Score
(Annual)
Level (-2.5724)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.3639)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Stock Forecast FAQ
In the current month, GH has received 14 Buy ratings 1 Hold ratings, and 0 Sell ratings. The GH average analyst price target in the past 3 months is $42.30.
-
Where Will Guardant Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Guardant Health share price will rise to $42.30 per share over the next 12 months.
-
What Do Analysts Say About Guardant Health?
Analysts are divided on their view about Guardant Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Guardant Health is a Sell and believe this share price will drop from its current level to $32.00.
-
What Is Guardant Health's Price Target?
The price target for Guardant Health over the next 1-year time period is forecast to be $42.30 according to 15 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is GH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Guardant Health is a Buy. 14 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GH?
You can purchase shares of Guardant Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Guardant Health shares.
-
What Is The Guardant Health Share Price Today?
Guardant Health was last trading at $30.43 per share. This represents the most recent stock quote for Guardant Health. Yesterday, Guardant Health closed at $30.44 per share.
-
How To Buy Guardant Health Stock Online?
In order to purchase Guardant Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
